BrainsWay Ltd. (NASDAQ:BWAY) Sees Significant Decrease in Short Interest

BrainsWay Ltd. (NASDAQ:BWAY) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 55,300 shares, a decline of 31.0% from the February 13th total of 80,200 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average daily volume of 65,600 shares, the short-interest ratio is currently 0.8 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of BrainsWay in a report on Wednesday, March 12th.

BrainsWay Stock Up 0.4 %

Shares of NASDAQ:BWAY opened at $10.25 on Monday. The stock has a market capitalization of $192.96 million, a PE ratio of 101.31 and a beta of 1.29. The firm’s 50 day moving average price is $10.26 and its 200-day moving average price is $9.63. BrainsWay has a twelve month low of $4.61 and a twelve month high of $11.79.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its stake in shares of BrainsWay by 316.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock worth $136,000 after purchasing an additional 11,221 shares in the last quarter. Rhumbline Advisers grew its holdings in BrainsWay by 10.8% during the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock valued at $207,000 after purchasing an additional 2,144 shares during the period. ARK Investment Management LLC purchased a new stake in BrainsWay in the fourth quarter worth about $1,656,000. Two Sigma Investments LP raised its stake in shares of BrainsWay by 2.0% in the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock worth $875,000 after buying an additional 1,786 shares during the period. Finally, Two Sigma Advisers LP lifted its position in shares of BrainsWay by 32.6% during the 4th quarter. Two Sigma Advisers LP now owns 60,600 shares of the company’s stock valued at $571,000 after buying an additional 14,900 shares in the last quarter. 30.11% of the stock is currently owned by institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.